Please enable Javascript
AHA Scientific Sessions 2020
Advertisement
AHA 2020 Wrap-Up with Payal Kohli, MD
DocWire News Editors
AHA Scientific Sessions 2020
|
December 13, 2020
Dr. Payal Kohli, a cardiologist with Cherry Creek Heart in Denver, and a DocWire News Section Advisor, talks about ...
View More
Rivaroxaban Plus Aspirin Reduced Cardiac, Limb Events in PAD After LER
DocWire News Editors
AHA Scientific Sessions 2020
|
April 11, 2023
Rivaroxaban plus aspirin reduced ischemic risk of the limb, brain, and heart in peripheral artery disease (PAD) after ...
Read More
Rivaroxaban Monotherapy Safe for AF After Coronary Stenting
DocWire News Editors
AHA Scientific Sessions 2020
|
November 24, 2020
The benefit of rivaroxaban monotherapy for patients with atrial fibrillation (AF) after coronary stenting was dependent ...
Read More
40% of Middle-Aged Swedes Had Silent CAD
DocWire News Editors
AHA Scientific Sessions 2020
|
April 11, 2023
Four out of 10 people in a middle-age population in Sweden had coronary artery disease (CAD), with one in 20 having ...
Read More
Rivaroxaban Plus Aspirin Protects Against Venous, Arterial Thrombotic Events After LER
DocWire News Editors
AHA Scientific Sessions 2020
|
November 18, 2020
Peripheral artery disease (PAD) was associated with continuous and linearly increasing risk for venous thromboembolism ...
Read More
Rivaroxaban Improved CV, Limb Events After Lower Extremity Revascularization in PAD with CKD
DocWire News Editors
AHA Scientific Sessions 2020
|
November 18, 2020
Rivaroxaban reduced major cardiovascular (CV) events and limb events in patients with peripheral artery disease (PAD) ...
Read More
GALACTIC-HF: Omecamtiv Mecarbil Reduced Risk of First HF Event, Death in HRrEF
DocWire News Editors
AHA Scientific Sessions 2020
|
April 10, 2023
In patients with heart failure with reduced ejection fraction (HFrEF), omecamtiv mecarbil significantly reduced the risk ...
Read More
Advertisement
Advertisement